Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1393-1402

  Thordardottir, Steinunn ^a,b   Ståhlbom, Anne Kinhult ^a   Ferreira, Daniel ^a   Almkvist, Ove ^a   Westman, Eric ^a   Zetterberg, Henrik ^c,d   Eriksdotter, Maria ^a,b   Blennow, Kaj ^c   Graff, Caroline ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; biomarkers; cerebrospinal fluid; genetics; magnetic resonance imaging; natural history studies; preclinical

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APP PROTEIN, HUMAN; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ADULT; ALZHEIMER DISEASE; APPARC GENE; APPSWE GENE; ARTICLE; FAMILIAL DISEASE; FEMALE; FUSIFORM GYRUS; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECUNEUS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PSEN1 GENE; SUPERIOR TEMPORAL GYRUS; SWEDEN; BRAIN; CEREBROSPINAL FLUID; COGNITION; FAMILY; GENETIC PREDISPOSITION; GENETICS; MUTATION; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PRODROMAL SYMPTOM;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; COGNITION; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; ORGAN SIZE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRESENILIN-1; PRODROMAL SYMPTOMS; SWEDEN; TAU PROTEINS;

EID: 84919930038     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140339     Document Type: Article

References (44)

1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 280-292.
2. Ringman JM (2005) What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: A review. J Geriatr Psychiatry Neurol 18, 228-233.
3. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
4. Reiman EM, Jagust WJ (2012) Brain imaging in the study of Alzheimer's disease. Neuroimage 61, 505-516.
5. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
6. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen OS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
7. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie XY, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med 367, 795-804.
8. Reiman EM, Quiroz YT, Fleisher AS, Chen KW, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JBS, Kosik KS, Tariot PN, Lopera F (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 11, 1048-1056.
9. Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM (2012) Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord 33, 1-5.
10. Apostolova LG, Hwang KS, Medina LD, Green AE, Braskie MN, Durron RA, Lai J, Geschwind DH, Cummings JL, Thompson PM, Ringman JM (2011) Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dement Geriatr Cogn Disord 32, 118-125.
11. Fortea J, Llado A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sanchez-Valle R (2011) Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis 8, 202-207.
12. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer's disease: A serial MRI study. Lancet Neurol 5, 823-834.
13. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the Nterminus of beta-amyloid. Nat Genet 1, 345-347.
14. Axelman K, Basun H, Winblad B, Lannfelt L (1994) A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation: A clinical and genealogical investigation. Arch Neurol 51, 1193-1197.
15. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4, 887-893.
16. Axelman K, Basun H, Lannfelt L (1998) Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. Arch Neurol 55, 698-702.
17. Clark RF, Hutton M, Fuldner RA, Froelich S, Karran E, Talbot C, Crook R, Lendon C, Prihar G, He C,Korenblat K, Martinez A, WraggM,Busfield F, Behrens MI,Myers A, Norton J,Morris J, Mehta N, Pearson C, Lincoln S, Baker M, Duff K, Zehr C, Pereztur J, Houlden H, Ruiz A, Ossa J, Lopera F, Arcos M, Madrigal L, Collinge J, Humphreys C, Ashworth A, Sarner S, Fox N, Harvey R, Kennedy A, Roques P, Cline RT, Phillips CA, Venter JC, Forsell L, Axelman K, Lilius L, Johnston J, Cowburn R, Viitanen M,Winblad B, Kosik K, Haltia M, Poyhonen M, Dickson D, Mann D, Neary D, Snowden J, Lantos P, Lannfelt L, Rossor M, Roberts GW, Adams MD, Hardy J, Goate A (1995) The structure of the Presenilin-1 (S182) gene and identification of 6 novel mutations in 6 early-onset AD families. Nat Genet 11, 219-222.
18. Keller L,Welander H, Chiang HH, Tjernberg LO, Nennesmo I, Wallin AK, Graff C (2010) The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: Clinical report and quantification of A beta in different brain regions. Eur J Hum Genet 18, 1202-1208.
19. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C,Wouters D, BlennowK(2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
20. Zetterberg H, Ruetschi U, Portelius E, Brinkmalm G, Andreasson U, BlennowK, BrinkmalmA(2008) Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 118, 1-11.
21. Blennow K,Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245.
22. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
23. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C (2011) The AddNeuroMed framework for multi-centre MRI assessment of longitudinal changes in Alzheimer's disease: Experience from the first 24 months. Int J Geriatr Psychiatry 26, 75-82.
24. Ségonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, Fischl B (2004) A hybrid approach to the skull stripping problem in MRI. Neuroimage 22, 1060-1075.
25. Sled JG, Zijdenbos AP, Evans AC (1998) A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17, 87-97.
26. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis I: Segmentation and surface reconstruction. Neuroimage 9, 179-194.
27. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97, 11050-11055.
28. Fischl B, Sereno MI, Tootell RBH, Dale AM (1999) High-resolution inter-subject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 8, 272-284.
29. Westman E, Aguilar C, Muehlboeck JS, Simmons A (2013) Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr 26, 9-23.
30. Genovese CR, Lazar NA, Nichols T (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15, 870-878.
31. Lezak MD (1995) Neuropsychological Assessment (3rd edition), Oxford University Press, New York.
32. Bergman I, BlombergM, Almkvist O (2007) The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol 48, 115-125.
33. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state-Practical method for grading cognitive state of patients for clinician. J Psychiatr Res 12, 189-198.
34. Cruts M, Backhovens H, Wang SY, Gassen GV, Theuns J, De Jonghe CD, Wehnert A, De Voecht J, De Winter G, Cras P, Bruyland M, Datson N, Weissenbach J, den Dunnen JT, Martin J-J, Hendriks L,Van BroeckhovenC(1995) Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet 4, 2363-2372.
35. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeaux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network (2014) Symptom onset in autosomal dominant Alzheimer disease:Asystematic review and meta-analysis. Neurology 83, 253-260.
36. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
37. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to betaamyloid peptide42. Arch Neurol 60, 1202-1206.
38. Almkvist O, Adveen M, Henning L, Tallberg IM (2007) Estimation of premorbid cognitive function based on word knowledge: The Swedish Lexical Decision Test (SLDT). Scand J Psychol 48, 271-279.
39. Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Langstrom B, Lannfelt L, Graff C, Nordberg A (2011) Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 32, 1388-1399.
40. Schöll M,Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, Almkvist O, Graff C, Nordberg A (2012) Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79, 229-236.
41. Möller C, Vrenken H, Jiskoot L,VersteegA, Barkhof F, Scheltens P, van der Flier WM (2013) Different patterns of gray matter atrophy in early-and late-onset Alzheimer's disease. Neurobiol Aging 34, 2014-2022.
42. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC (2009) High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 66, 1537-1544.
43. Rabinovici GD, Jagust WJ (2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol 21, 117-128.
44. Fortea J, Sala-Llonch R, Bartrés-Faz D, Bosch B, Lladó A, Bargalló N,Molinuevo JL, Sánchez-Valle R (2010) Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis 22, 909-922.